On the public citation graph

Clinically-weighted transcriptomic signatures for protein kinase inhibitor associated cardiotoxicity

0 signed · 73 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cpdd.77openalex-snapshot
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients
inferredcites →https://doi.org/10.1002/jcph.109openalex-snapshot
Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
inferredcites →https://doi.org/10.1002/jcph.263openalex-snapshot
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites
inferredcites →https://doi.org/10.1002/wsbm.114openalex-snapshot
Role of systems pharmacology in understanding drug adverse events
inferredcites →https://doi.org/10.1007/978-1-61779-337-0_1openalex-snapshot
Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors
inferredcites →https://doi.org/10.1007/bf03259793openalex-snapshot
Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
inferredcites →https://doi.org/10.1007/s00280-011-1688-7openalex-snapshot
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
inferredcites →https://doi.org/10.1007/s00280-011-1803-9openalex-snapshot
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
inferredcites →https://doi.org/10.1007/s00280-012-1888-9openalex-snapshot
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
inferredcites →https://doi.org/10.1007/s00280-013-2324-5openalex-snapshot
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
inferredcites →https://doi.org/10.1007/s00280-014-2484-yopenalex-snapshot
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
inferredcites →https://doi.org/10.1007/s10549-013-2707-7openalex-snapshot
Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents
inferredcites →https://doi.org/10.1007/s10565-006-0140-yopenalex-snapshot
Adriamycin-induced oxidative mitochondrial cardiotoxicity
inferredcites →https://doi.org/10.1007/s11095-012-0845-yopenalex-snapshot
Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab
inferredcites →https://doi.org/10.1007/s11523-014-0333-xopenalex-snapshot
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
inferredcites →https://doi.org/10.1016/j.bbrc.2010.09.075openalex-snapshot
Fast kinase domain-containing protein 3 is a mitochondrial protein essential for cellular respiration
inferredcites →https://doi.org/10.1016/j.cellsig.2010.01.011openalex-snapshot
Kinases as targets in the treatment of solid tumors
inferredcites →https://doi.org/10.1016/j.coph.2014.07.015openalex-snapshot
Recently targeted kinases and their inhibitors—the path to clinical trials
inferredcites →https://doi.org/10.1016/j.drudis.2008.05.011openalex-snapshot
Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem
inferredcites →https://doi.org/10.1016/j.jchromb.2008.09.007openalex-snapshot
Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry☆
inferredcites →https://doi.org/10.1016/j.taap.2010.08.026openalex-snapshot
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
inferredcites →https://doi.org/10.1016/j.taap.2013.04.027openalex-snapshot
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes
inferredcites →https://doi.org/10.1016/j.yjmcc.2013.12.002openalex-snapshot
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21Cip1
inferredcites →https://doi.org/10.1016/s0140-6736(07)61865-0openalex-snapshot
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
inferredcites →https://doi.org/10.1016/s0140-6736(12)60398-5openalex-snapshot
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
inferredcites →https://doi.org/10.1038/clpt.2009.208openalex-snapshot
Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
inferredcites →https://doi.org/10.1038/clpt.2011.74openalex-snapshot
Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
inferredcites →https://doi.org/10.1038/nbt.1990openalex-snapshot
Comprehensive analysis of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/nbt.3374openalex-snapshot
Comprehensive characterization of the Published Kinase Inhibitor Set
inferredcites →https://doi.org/10.1038/nm1446openalex-snapshot
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
inferredcites →https://doi.org/10.1038/nmeth.1778openalex-snapshot
Counting absolute numbers of molecules using unique molecular identifiers
inferredcites →https://doi.org/10.1038/nrc2106openalex-snapshot
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
inferredcites →https://doi.org/10.1038/nrd3252openalex-snapshot
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
inferredcites →https://doi.org/10.1046/j.0014-2956.2001.02473.xopenalex-snapshot
The role of protein phosphorylation in human health and disease.
inferredcites →https://doi.org/10.1053/j.seminoncol.2011.01.014openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors
inferredcites →https://doi.org/10.1056/nejmoa1311107openalex-snapshot
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1074/jbc.m111.315812openalex-snapshot
Inhibition of AMP-activated Protein Kinase α (AMPKα) by Doxorubicin Accentuates Genotoxic Stress and Cell Death in Mouse Embryonic Fibroblasts and Cardiomyocytes
inferredcites →https://doi.org/10.1080/02841860903229124openalex-snapshot
Cardiotoxicity induced by tyrosine kinase inhibitors
inferredcites →https://doi.org/10.1093/bioinformatics/btp324openalex-snapshot
Fast and accurate short read alignment with Burrows–Wheeler transform
inferredcites →https://doi.org/10.1093/bioinformatics/btp616openalex-snapshot
edgeR : a Bioconductor package for differential expression analysis of digital gene expression data
inferredcites →https://doi.org/10.1093/cvr/cvv152openalex-snapshot
Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism
inferredcites →https://doi.org/10.1093/toxsci/kfn157openalex-snapshot
Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
inferredcites →https://doi.org/10.1093/toxsci/kfu235openalex-snapshot
Downregulation of Stanniocalcin 1 Is Responsible for Sorafenib-Induced Cardiotoxicity
inferredcites →https://doi.org/10.1097/qai.0b013e3181f25946openalex-snapshot
Role of Pyrimidine Depletion in the Mitochondrial Cardiotoxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors
inferredcites →https://doi.org/10.1101/003236openalex-snapshot
Characterization of directed differentiation by high-throughput single-cell RNA-Seq
inferredcites →https://doi.org/10.1111/bcp.12143openalex-snapshot
Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate‐associated neutropenia
inferredcites →https://doi.org/10.1111/j.1467-9868.2005.00503.xopenalex-snapshot
Regularization and Variable Selection Via the Elastic Net
inferredcites →https://doi.org/10.1124/dmd.113.054940openalex-snapshot
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
inferredcites →https://doi.org/10.1126/scisignal.2000723openalex-snapshot
Systems Pharmacology of Arrhythmias
inferredcites →https://doi.org/10.1126/scitranslmed.3006548openalex-snapshot
Systems Pharmacology of Adverse Event Mitigation by Drug Combinations
inferredcites →https://doi.org/10.1146/annurev-pharmtox-011112-140248openalex-snapshot
Systems Pharmacology to Predict Drug Toxicity: Integration Across Levels of Biological Organization
inferredcites →https://doi.org/10.1146/annurev-physiol-021909-135931openalex-snapshot
The FoxO Family in Cardiac Function and Dysfunction
inferredcites →https://doi.org/10.1152/ajpheart.00554.2015openalex-snapshot
Drug-induced mitochondrial dysfunction and cardiotoxicity
inferredcites →https://doi.org/10.1158/0008-5472.can-08-0499openalex-snapshot
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-2740openalex-snapshot
Phase I Trial of Pazopanib in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1177/0091270010389469openalex-snapshot
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
inferredcites →https://doi.org/10.1200/jco.2004.06.075openalex-snapshot
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
inferredcites →https://doi.org/10.1200/jco.2005.01.3441openalex-snapshot
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1200/jco.2005.02.2194openalex-snapshot
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
inferredcites →https://doi.org/10.1200/jco.2005.02.840openalex-snapshot
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2005.04.192openalex-snapshot
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
inferredcites →https://doi.org/10.1200/jco.2007.14.9633openalex-snapshot
Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer
inferredcites →https://doi.org/10.1200/jco.2008.20.4818openalex-snapshot
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.3509openalex-snapshot
Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
inferredcites →https://doi.org/10.1200/jco.2010.32.4145openalex-snapshot
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
inferredcites →https://doi.org/10.1200/jco.2012.43.5966openalex-snapshot
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
inferredcites →https://doi.org/10.1371/journal.pone.0048929openalex-snapshot
Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12
inferredcites →https://doi.org/10.2165/00002018-199920020-00002openalex-snapshot
The Medical Dictionary for Regulatory Activities (MedDRA)
inferredcites →https://doi.org/10.5966/sctm.2015-0279openalex-snapshot
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1016/j.ijcard.2020.05.077openalex-snapshot
Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
inferred← citeshttps://doi.org/10.1016/j.taap.2022.116162openalex-snapshot
A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model
inferred← citeshttps://doi.org/10.1038/s41598-017-18524-2openalex-snapshot
Putative functional genes in idiopathic dilated cardiomyopathy
inferred← citeshttps://doi.org/10.1101/2020.02.26.966606openalex-snapshot
Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity: Mount Sinai DToxS LINCS Center Dataset
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.